Advances in diabetic cardiomyopathy: current and potential management strategies and emerging biomarkers

Diabetic cardiomyopathy (DCM) is a significant complication of diabetes mellitus (DM) and a major contributor to heart failure (HF). Despite its prevalence and impact, there is a notable lack of targeted therapies, highlighting the need for ongoing research into novel treatment strategies. Current management primarily involves blood sugar control, lifestyle modifications, and addressing risk factors. Conventional treatments, including Renin-angiotensin-aldosterone system (RAAS) inhibitors, angiotensin receptor/neprilysin inhibitor, beta-blockers, ivabradine, and vericiguat, are also employed.

A comprehensive search was made using PubMed, Scopus, and Google Scholar for studies published. The search focused on DCM, therapeutic strategies, and emerging biomarkers. Articles were selected based on relevance, study quality, and inclusion criteria, which emphasized peer-reviewed studies on DCM management and biomarker identification.

Our review reveals that targeting oxidative stress through these antioxidant therapies offers a promising approach for limiting DCM progression. Clinical trials provide evidence supporting the efficacy of these agents in reducing oxidative damage and improving cardiac function in diabetes-induced cardiomyopathy.

The current landscape of DCM management highlights the need for novel therapeutic strategies and early detection methods. Antioxidant therapies show potential for addressing the oxidative stress that underlies DCM, and ongoing research into emerging biomarkers may offer new avenues for early diagnosis and treatment.